Louis-Charles Precision Medicine Made for You

Plain Talk of How Precision Medicine Is Using Your Genes, Your Data, and Your Biology to Reinvent Healthcare
1. Auflage 2026
ISBN: 979-8-90498-042-9
Verlag: PublishDrive
Format: EPUB
Kopierschutz: 0 - No protection

E-Book, Englisch, 353 Seiten

Reihe: PublishDrive

Medicine, Made for You is a plain-language guide to precision medicine written for patients, families, caregivers, students, journalists, advocates, and curious general readers who keep encountering pharmacogenomics, genomic profiling, polygenic risk scores, and gene therapies in headlines and clinical conversations and want to understand what the words mean, what the tests actually do, and what to ask for. The book takes no biology or medical background for granted, builds the science from first principles, and grounds every chapter in a sustained narrative inside Meridian Health Partners, a fictional twelve-hundred-bed academic health system in the Texas Medical Center.
The book opens with the structural failure that motivates the field. The average patient does not exist. Clinical trials measure outcomes across populations and report means; medicine practiced from those means treats every patient as if they were the average, and the patients who are not average-who metabolize a drug too quickly or too slowly, who carry a variant the trial never measured-are the patients who account for the 250,000 to 300,000 preventable adverse-drug-event deaths that occur every year in the United States. Robert Tillman, a school-bus driver in Galveston County who survives a near-fatal warfarin reaction, opens the book; the system that almost killed him is the system the rest of the book is about transforming.
From that opening, ten chapters develop the science and practice of precision medicine in the same voice: explanation before significance, mechanism before metaphor, and the patient before the policy. Chapter 1 establishes why one-size-fits-all medicine fails real people. Chapter 2 is the science chapter-genomics, DNA sequencing, biomarkers, and epigenetics in plain English. Chapter 3 covers pharmacogenomics and the preemptive PGx panels that prevent cases like Robert's. Chapter 4 develops comprehensive genomic profiling in cancer and the targeted therapies it has unlocked. Chapter 5 covers whole-genome sequencing for rare disease and the first generation of CRISPR gene therapies, including Casgevy. Subsequent chapters address polygenic risk scores in cardiovascular disease and diabetes, precision oncology, microbiome and metabolomic profiling, the data infrastructure-electronic health records, biobanks, the NIH All of Us Research Program-that makes the field possible, the access and equity questions that determine who actually benefits, and the policy frameworks that govern privacy, insurance discrimination, and informed consent.
Four recurring characters carry the arc. Dr. Amara Osei, the chief genomics officer fighting institutional inertia. James Kowalski, the pharmacist who becomes the institution's preemptive-PGx advocate after watching a near-fatal reaction unfold. Sofia Reyes, the navigator who sits between the genomics laboratory and the families waiting for results they cannot read. Dr. David Chen, the skeptic whose worldview shifts when his sister's lung cancer reveals an actionable EGFR mutation. Each chapter opens at Meridian, then spirals outward to the science and institutions reshaping medicine globally. The characters are fictional. The science is real.
By the final chapter, readers will understand what precision-medicine tests to ask for, what results actually mean, how to advocate inside a healthcare system that has not yet caught up to its own science, how to evaluate access and equity questions, and how to participate informedly in the conversations-clinical, ethical, and political-that will determine who benefits from this era of medicine.

Autoren/Hrsg.

Louis-Charles, Claude

Leseproben

Introduction

The Average Patient

The chart says a fifty-four-year-old male, one hundred and seventy-eight pounds, with a history of atrial fibrillation. His name is Robert Tillman. He drives a school bus in Galveston County, cares for his elderly mother on weekends, and has taken warfarin for three years to prevent the blood clots that could send a stroke crashing through his life. His cardiologist is careful. The dose has been adjusted twice by the textbook, guided by INR numbers and population-level guidelines written for a theoretical average patient. Robert is not that patient. No one is.

On a Thursday morning in late October, Robert wakes up with a headache unlike any he has felt before, a pressure behind his left eye that feels like something pressing from inside. His wife drives him to the ER, where the CT reveals a small intracranial hemorrhage. His warfarin level is too high. The drug prescribed to prevent a stroke has, in his particular body, helped cause one. Later lab work reveals that Robert carries a variant in his CYP2C9 gene, which gives him a metabolizer profile that makes his body process warfarin far more slowly than average. A simple pharmacogenomic test, available at most clinical labs for under three hundred dollars, could have flagged that variant before his very first dose. The right drug at the right dose, calibrated to his biology, would have looked nothing like what he received.

Robert's story is not a story of negligence. It is medicine practiced exactly as it was designed, on a patient it was never quite designed for. This book is about that gap.

Statistical Fiction

Modern medicine has performed miracles: eradicating smallpox, transforming HIV into a manageable condition, and turning once-fatal childhood cancers into survivable diseases. Those achievements deserve full acknowledgment. And yet the architecture underneath them rests on a fiction: the fiction of the average patient.

When a drug enters clinical trials, researchers measure outcomes across a group, calculate means, and report findings that describe the population but cannot predict what will happen inside any individual. The dosing guidance on the approved drug's package insert reflects what the median trial participant experienced. Your physician, armed with those guidelines, is prescribing for a statistical average, not for you.

The consequences are not abstract. Adverse drug events are now estimated to cause between 250,000 and 300,000 deaths annually in the United States, making them one of the leading causes of preventable mortality. More than 1.5 million Americans visit emergency departments each year because of adverse drug reactions. The same logic also produces chemotherapy regimens that work for sixty percent of patients and do almost nothing for the other forty, antidepressants cycled through by trial and error over months or years, and screening programs that catch cancer at stage three or four rather than stage one, when treatment is most likely to work.

What Has Changed

The revolution has been building for two decades and is now arriving in clinical practice faster than most patients realize. The catalyst was sequencing the human genome. When the Human Genome Project published its first working draft in 2001, sequencing a single genome cost roughly $2.7 billion. Today, next-generation sequencing has driven the cost below $200, with clinical turnaround times measured in days. That cost collapse is one of the fastest technological deflations in the history of science, and it has cracked open a door sealed for most of medical history: the ability to look inside an individual patient's biology and ask specifically what is happening in this person, not in a population that resembles them.

Diagram I.1 - The Cost of Sequencing a Human Genome, 2001 to 2024

Precision medicine, treatment tailored to your genes, your biology, and your individual circumstances, is the field that has grown from that opening. It is not a single technology. It is a philosophy and a growing clinical infrastructure built around the idea that the right treatment for any given patient depends on understanding who that patient actually is at the molecular level. The global market for precision medicine reached $87.5 billion in 2023 and is projected to reach $249 billion by 2030, growing at a compound annual rate of 16.3 percent. That trajectory reflects real clinical adoption, not speculative hype.

Consider what this has made possible. The NIH's All of Us Research Program has enrolled more than one million participants, building the most diverse biomedical research dataset in history. Foundation Medicine's FoundationOne CDx analyzes more than three hundred cancer-related genes from a single tumor biopsy, matching patients to targeted therapies rather than broad chemotherapy. GRAIL's Galleri liquid biopsy test detects cell-free DNA from more than 50 cancer types in a single blood draw; the PATHFINDER 2 study of 35,878 participants showed that adding Galleri to standard screening increased cancer detection by more than 7-fold. In December 2023, the FDA approved Casgevy, the first CRISPR-based gene therapy, which effectively cures sickle cell disease by editing a patient's own blood stem cells. These are not pilot projects. They are approved, available, and expanding.

Why This Book Exists

I have spent my career at the intersection of genomics, healthcare systems, and the humans those systems are supposed to serve. I have watched precision medicine move from a compelling promise to clinical reality, and I have seen that shift unfold unevenly: quickly at top academic centers, slowly or not at all in community hospitals and rural clinics. I have watched patients receive diagnoses that changed everything, not because their disease was newly different, but because someone finally ran the test that identified what was actually driving it. And I have watched patients who never knew how to ask.

That gap, between what precision medicine can now do and what most patients know to request, is the reason this book was written. Many labs offer pharmacogenomic panels that predict how a patient will metabolize dozens of common medications for $150 to $300. Medicare covers comprehensive genomic tumor profiling for the most advanced solid tumors. Preemptive genetic screening programs for hereditary cancer risk are running at health systems across the country. Patients cannot advocate for tests they do not know exist.

This book translates the language of genomics and molecular biology into the language of Tuesday mornings and difficult conversations with clinicians and frightened family members. It is written for the curious, non-specialist reader who wants to understand not just that precision medicine exists but how it works, what it can do today, and what it means for them.

A Note on Meridian

Science is easier to understand inside a human story. Throughout this book, you will follow Meridian Health Partners, a fictional one-thousand-two-hundred-bed academic health system in the Texas Medical Center in Houston, one of the most ethnically diverse patient populations in the United States. Meridian is a composite built from real institutional patterns and real challenges. It is not a portrait of any single institution, but everything that happens there reflects something that has happened, or is happening, somewhere.

Four recurring characters carry the arc.

• Dr. Amara Osei, Chief Genomics Officer: a geneticist recruited to transform Meridian after a cascade of adverse drug events, who will spend the book fighting institutional inertia and skeptics who see precision medicine as an expensive aspiration.

• James Kowalski, PharmD: a twenty-year veteran clinical pharmacist who witnesses a near-fatal drug reaction a simple PGx test could have prevented, and becomes Meridian's fiercest advocate for preemptive pharmacogenomic testing.

• Sofia Reyes, patient navigator: the person who sits between the genomics laboratory and the families waiting for results they cannot read, translating science into language people can act on and fighting insurance denials one case at a time.

• Dr. David Chen, oncologist: a traditionalist skeptic whose worldview shifts when his own sister Lisa is diagnosed with advanced non-small cell lung cancer and comprehensive genomic profiling reveals an ALK rearrangement that opens the door to a targeted therapy, changing her prognosis entirely.

Each chapter opens at Meridian, then spirals outward to the same science reshaping medicine globally. The characters are fictional. The science is real.

How To Read This Book

This book is organized as a journey from problem to solution, from the foundational science to its most advanced frontiers, and from the individual patient to the systems and policies that will determine how equitably precision medicine's benefits are distributed. Each chapter builds on what came before, but most can also stand on their own if a specific topic is what brought you here. Here is a brief map.

• Chapter 1, The Average Patient Does Not Exist: Maria Santos, a thirty-seven-year-old teacher, becomes the lens through which we examine how one-size-fits-all medicine fails real people, and what a precision approach could have changed.

• Chapter 2, Reading the Book of You: the science chapter. Genomics, DNA sequencing, biomarkers, and epigenetics in plain English. Your genome is the recipe book; mutations are typos that change what gets cooked. This is the operating manual for the chapters that follow.

• Chapter 3, Right Drug, Right Dose, Right Person: pharmacogenomics and how your genetic variants determine how your body...